SEATTLE & BALTIMORE--(BUSINESS WIRE)--June 2, 2006--Targeted Genetics Corporation (Nasdaq:TGEND - News) is reporting new developments in its portfolio of AAV manufacturing capabilities at the American Society of Gene Therapy (ASGT) 2006 Annual Meeting. One advance, reported yesterday afternoon in a poster, titled "Clearance of Helper Adenovirus by an AAV1 Clinical Vector Manufacturing Process" (Abstract #312), describes a robust method for producing adeno-associated virus type 1 (AAV1) vectors. The other, which will be presented today in a poster, titled "Improving the Stability of Ad-AAV Hybrid Vectors" (Abstract #499), enables another proprietary, scalable AAV manufacturing process that may be applicable to commercial production.
